跳至主要内容
临床试验/CTRI/2016/06/007001
CTRI/2016/06/007001已完成4 期

TO COMPARE THE EFFECT OF BENZALKONIUM CHLORIDE-PRESERVED LATANOPROST AND BENZALKONIUM CHLORIDE-FREE LATANOPROST ON OCULAR SURFACE HEALTH IN PATIENTS OF PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSIO

Government Medical College Patiala0 个研究点目标入组 30 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
已完成
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Established cases of POAG or ocular hypertension with IOP controlled on monotherapy of BKC-preserved latanoprost for more than three months.

排除标准

  • 1 Known lack of ocular hypotensive response to topical ophthalmic, prostaglandin analogs (in the opinion of the investigator).
  • 2 Intraocular conventional surgery or laser surgery within the past one year.
  • 3 Any refractive surgery in study eye .
  • 4 Patients on steroids medication.
  • 5 Ocular trauma within the past 3 months.
  • 6 Patients suffering from Rheumatoid arthritis or any other systemic disease which also causes dry eye.
  • 7 Patients taking any other medication which also causes dry eye.
  • 8 Progressive retinal or optic nerve disease apart from glaucoma.
  • 9 Concurrent infectious/non infectious conjunctivitis, keratitis, or uveitis in either eye.
  • 10 Any abnormality preventing stable applanation tonometry.
  • 11 Use of contact lens for the duration of the study.
  • 12 Any opacity or subject uncooperativeness that restricts adequate examination of the ocular fundus or anterior chamber.
  • 13 Clinically significant ocular disease (e.g., corneal edema, uveitis, severe keratoconjunctivitis sicca) which might interfere with the study,.
  • 14 Clinically significant systemic disease which might interfere with the study.
  • 15 History of non-compliance to medical regimens or unwilling to comply with the study protocol.
  • 16 Patients with hypersensitivity or poor tolerance to any components of the study medication.
  • 17 Angle closure glaucoma or a history of acute angle closure treated with a peripheral iridotomy.
  • 18 Participation in another clinical study within the last thirty (30) days.

研究者

相似试验